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ABSTRACT
Currently, the most commonly used treatm ents for cancerous tum ors (chemother­
apy, radiation, etc.) have almost no method of monitoring the adm inistration of the 
treatm ent for adverse effects in real time. W ithout any real time feedback or control, 
treatm ent becomes a “guess and check” method with no way of predicting the effects 
of the drugs based on the actual bioavailability to the patient’s body. One particular 
drug may be effective for one patient, yet provide no benefit to another. Doctors and 
scientists do not routinely attem pt to  quantifiably explain this discrepancy.
In this work, mathematical modeling and analysis techniques are joined to­
gether with experimentation to  gain further insight into the challenges of nanoparticle 
uptake and retention in the bloodstream. Several models are presented here which 
predict both the uptake and retention phases of the experiment. There does exist 
a commonly accepted model of drug clearance in the pharmacokinetics community, 
and it is demonstrated here that this model provides an accurate reflection of reality, 
as observed in experiments, for delivery of gold-coated nanorods. This model is then 
utilized in a state space feedback control framework to regulate the nanoparticle con­
centration in the bloodstream. An equal time delay is also introduced in both the 
state and control input for the purpose of studying alternate dosing strategies. This 
study will aid in the prediction of the effects of the drugs in a patien t’s body, thus 
leading to better models for drug regimen and administration.
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CHAPTER 1
INTRODUCTION
Though cancer therapies can be effective, there is almost no way to predict 
the effect that a particular therapy will have on any one individual [34]. As current 
treatm ent dosages are largely determined by the weight of the subject, there is 
almost no way of predicting the efficacy or any adverse effects while the drug is 
being administered. M athematical models and controls have been applied towards 
developing strategies which would determine when and how much of a drug to  inject to 
produce a prolonged and effective therapeutic result [10], [11], [12], [23], [39]. However, 
the combination of mathematical models with real-time clinical da ta  could assist in 
providing better quality control in dosing. Predictive models could further help in 
identifying adverse events prior to the onset of signs and symptoms.
In recent years, clinical studies have been carried out for measurements of the 
uptake and clearance of engineered gold nanoparticles in the tissues of dosed mice 
[18], [26], [27], [28], [29]. These devices are under consideration for a new therapy for 
cancerous tumors. Clinical trials in animals are currently underway to  investigate the 
therapeutic bioavailability of nanoparticles used in the treatm ent of these tum ors in a 
technique known as nanoparticle-assisted phototherm al cancer therapy, such as in [26] 
and [27]. The research presented here investigates the development of m athem atical
1
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models to estimate in real-time the circulation param eters of models, from which we 
calculate the area-under-the-curve (AUC) and half-life towards a clinical application. 
These particular variables can be telling of the overall retention of the nanoparticles 
[17], [28], as will be discussed in Chapter 2.
In this dissertation, we present a framework for the least error models of the 
experiments th a t can be created in real tim e (that is, within the tim e of which the 
experiment is run). Many different modeling methods were considered for this work 
that dealt with separating the body into different compartments (i.e. the reticulo­
endothelial system, the tumor, the lungs, etc.) [17], [20], [37], [38] and also those 
that dealt with only a single compartment (the entire body a t once) [5], [9], [14], 
[15], [22]. It was decided, for this work, to model a single compartment. This is due 
to a lack of clinical data for accumulation in the tum or, clearance by the Reticulo 
Endothelial System, etc. W ithout this data  is not possible to accurately model what 
is happening in the separate compartments of the body. Several different models are 
presented, each of which provides a best fit for different times in the experiments. 
We start with a rational function model which mimics models th a t were found in the 
literature that include both the uptake and retention phases [17]. We then show the 
exponential model in order to have a model which focuses strictly on the retention 
phase of the experiment. Also, in an effort to  improve upon the skewed rational model, 
an absolute value model is presented. Finally, a piecewise function is presented which 
combines a certain desired shape for the injection phase of the experiment and the 
already found exponential best fit for the retention phase.
3
Upon completion of these models, statistical tests were employed to  determine 
if the data were correlated enough to take averages without losing generality. The 
Spearman Ranked Correlation test was done on several different pairs of data  sets to 
determine whether or not certain experimental variables were related. The Wilcoxon 
Signed Rank test was then performed to ensure that every value within each individual 
data set was statistically similar. We then averaged each model for each set of data 
and created confidence bounds and prediction intervals. These averaged models, or 
‘Master Mice’, were calculated, along with the confidence and prediction intervals, so 
that, in future experiments, adverse reactions (such as allergic reactions or significant 
clearance rates) may be detected within the time of the  experiment and changes in 
dosage rates can be made accordingly. The ‘M aster Mice’ also provide appropriate 
data sets to test using the controllers th a t are discussed in Chapters 4 and 5.
A Linear Quadratic Regulator (LQR) tracking controller (as discussed in [7] 
and [4]) was then applied to the averaged models, or ‘Master Mice’. This controller 
was implemented on a delay differential equation model and included a tracking fea­
ture to regulate the bloodstream nanoparticle concentration to  a desired absorbance 
value (measured in OD). Currently, the controller is only applied to the exponential 
model as this is the most commonly referenced model in the literature. However, as a 
delay differential equation takes the history of the function into account, the injection 
phase of the piecewise model is included here. This controller is further analyzed by 
changing the amount of the initial injection in order to investigate the possibility 
of limiting the total amount of nanoparticles required experimentally. Dirac delta 
functions are then used in place of the continuous tim e controller to  determine the
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efficacy of a discrete amount of injections to control the absorbance level as opposed to 
the continuous injection used in the LQR controller. Finally, a Proportional Integral 
Derivative (PID) controller for a delay differential equation (similar to those discussed 
in [33]) is applied to  the problem in an attem pt to control not only the absorbance 
value (in OD) over time but the area under the curve as well.
The goal of this work is to be able to use the model and controller in real 
time during the injection and elimination phase of nanoparticle adm inistration to a 
subject. The use in real time situations would provide feedback in case of adverse 
reaction or if the dose needs to be increased or decreased according to the subject’s 
reaction. Ideally, the feedback controller would also be used during the experiment 
so that the optimal level of nanoparticles would circulate through the bloodstream 
for the maximum allowable time.
Chapter 2 contains background information of the experimental work th a t is 
has been done to obtain the data  and also describes each of the least error models, 
along with the method that was employed to obtain the models. Chapter 3 describes 
the statistical tests th a t were run on the data  and discusses what the results represent, 
along with a description of the average models with the corresponding confidence and 
prediction intervals. The control strategies and results are discussed in Chapters 4 
and 5. Finally, in Chapter 6  we conclude with observations and future work.
CHAPTER 2 
LEAST ERROR MODELS
2.1 E xperim ental D esign
The objective of the pre-clinical experiment from which the da ta  reported here 
was obtained was to investigate the pharmacokinetic properties of therapeutic gold 
nanorods. These 40-nm diameter gold nanorods were manufactured by Nanospectra 
Biosciences, Inc (NBI) (Houston, TX) and are used for the phototherm al ablation of 
tum or cells [1], [32]. That is, the nanorods are first injected into the bloodstream; 
then, upon collection in the tum or, the nanorods are given laser treatm ent th a t causes 
them to heat to the point of killing the vasculature of the tumor, thus killing the tumor. 
They are used in the experiments from which the da ta  is collected specifically with 
murine colon carcinomas. These tumors are grown on the flank of the mouse just 
beneath the skin until the tum or reaches the desired size. Once the tum or was the 
appropriate size, the nanorods were injected and circulation da ta  was collected.
The data was collected by the O ’Neal group in the Biomedical Engineering 
program at Louisiana Tech University in collaboration with NBI. The real-time blood 
concentration of the nanorods was monitored using a novel non-invasive optical device 
similar to a pulse oximeter [26], [27], [28]. This experimental pulse photometer,
5
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also referred to  as the ‘NanoTracker’, uses the  technique of multi-wavelength pho­
toplethysmography [1]. The NanoTracker measures the attenuation of near-infrared 
wavelengths as nanorods are introduced into the  pulsatile bloodstream of the subject 
and quantifies the circulating dose in near real-time in terms of optical density units 
(OD) [26], [27], [28]. An OD unit refers to the quantity of absorbance of the nanorods. 
The quantity of absorbance of the nanorods is indicative of the actual concentration 
of nanorods circulating a t th a t time.
The experiment in which the d a ta  was collected employed two groups of ~20g 
BALB/c mice to examine the variability of nanorod circulation param eters and their 
effects on related clinical pharmacokinetic variables such as tum or uptake. The ~100 
OD nanorods were intravenously injected at dosages of either 4.5/xL/gm (lx ) or 
9 /zL/gm (2x) body weight at the rate of 18/rl/min. At discrete time points post­
injection, the NanoTracker was placed on the tail of the mouse and measurements 
were taken a t regular intervals until which time the observed optical density reached 
a level of 1 OD ±10%. The data  was later used to produce a bioavailability curve 
and to compute typical measurements of performance such as AUC and half-life. The 
bioavailability curve th a t was produced here is not the same as th a t which is found 
by any of the least error models presented in this chapter.
2.2 Least Error M odels
It is im portant to be aware that, as the measurements were taken at discrete 
time intervals and not continuously for the duration of the experiment, the highest 
or lowest points in the observed data  do not necessary reflect the actually highest
7
and lowest points tha t occur in reality. For this reason, more points are interpolated 
using the observed data points. This process is described in Subsection 2.2.1. The 
data is separated into two phases: the injection phase, or uptake, and the elimination 
phase, or retention, which refers to how long the nanoparticles are actually staying 
in the body. Currently, the literature mostly focuses on modeling the retention phase 
by itself [17]. As it is im portant for this study to  model both phases of the data, 
three different models are created and a minimal search algorithm  is performed 
using MATLAB® in order to  find the best fit between the experimental da ta  and 
the mathematical models.
2.2.1 Error D eterm ination
The function against which the respective models were compared was a piece- 
wise exponential function. This was created by determining an exponential function 
which fit each pair of consecutive experimental da ta  points. The algorithm was 
written to insure the function started at zero for each set of da ta  and also term inated 
at the final data point (as opposed to assuming an exponential decay or rise past that 
point). For the sake of conciseness, this function will be defined as A(t).
Initially, the error was calculated using the standard Euclidian norm, shown
where N  :=  total number of points in A(t).  y — y := the error in the y-direction
This calculation evolved to evaluating the error using the  standard R-squared value
in (2 .1 )
between the model to be found and the approximated experimental function A(t).
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for ease of comparison to  other models in the literature and also because this is the 
more generally accepted error calculation. The R-squared value is defined in (2.2)
r>2 _ i £ < ((*  — Vi)2) fn o\R =  1"  r.Mvi - m ’ ( 2 ' 2 )
where y — y := the error in the y-direction between the model to be found and the 
approximated experimental function A(t )  and yi — y  :=  the difference between the 
function A(t)  and the mean value of .4(f). A model which yields an R-squared value 
close to one is considered a good fit and implies low errors.
Though utilizing the calculated R-squared as the value to  be minimized when 
finding each model was appropriate for comparison purposes, it proved to be a weak 
determination of overall error between a model and A(t )  as it only took the error 
in y-direction into account. It was observed in the models th a t though there may
have been a large difference in the y-direction, the values in the x-direction were
quite close. In order to better represent the overall error for each model, the Total 
Least Squared (TLS) method given in [30] was performed. This m ethod found the 
orthogonal distance between each point on the particular model and the nearest point 
(considering both the x and y-directions) in A(t).  The to tal error in this method was 
defined as the sum of these distances squared. As this value is comparable to  the 
numerator of (2 .2 ), in order to  be able to compare each error calculation with ease, 
the ‘TLS-squared’ value is calculated by replacing the numerator of (2.2) with the 
TLS error value. Both the R-squared and ‘TLS-squared’ error values are calculated 
for each model that is presented and values close to one imply good fits.
9
2.2.2 R ational M odel
Both the uptake and retention phases of the data  were initially modeled using 
a rational expression. As this expression models both the uptake and the retention 
phase, it is particularly useful for predictive purposes such as early diagnosis of 
adverse reactions to the nanoparticles. After considering several different functions 
(polynomials of varying degrees, logistic equation, and trigonometric functions), the 
following equation was found to  represent the experimental data  well and yielded low 
error when the aforementioned minimal search algorithm was performed:
with a,P,  and 7  being real-valued param eters determined from the minimal search 
algorithm and t time (in minutes). As an example, Figure 2.1 shows this model with 
its corresponding R-squared value for one particular mouse.


















200 400 600 1000 1200 1400
Figure 2.1: Approximated rational curve found using R-squared (left) and TLS 
(right)
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This function yields acceptably low R-squared values and gives a good esti­
mation of the uptake and retention phases of the nanoparticles. However, the peak 
absorbance value (in OD units) is skewed towards the right of the experimental peak 
for each mouse modeled, and it also tends to show too sharp of a drop immediately 
following the peak absorbance when compared to  experimental observations.
2.2.3 E xponential M odel
Though the rational model is useful for predictive purposes, an exponential 
decay which models only the elimination of nanoparticles from the bloodstream  is the 
more generally accepted model in pharmacokinetics [17]. Of course, even though the 
nanoparticles are not drugs and are generally inert, they must still clear them, so the 
exponential model which highlights the elimination phase was naturally considered as 
a possibility. This model begins at the peak d a ta  point, where the nanoparticles are 
at the highest observed concentration in the bloodstream. Dr. O ’Neal and his team 
theorize that the reason for the sharp drop in concentration after the nanoparticle 
peak in the algebraic model is because of poorly coated nanoparticles th a t are in 
the batch. As the nanoparticles must be coated with something to keep the body 
from eliminating them immediately upon detection, the nanoparticles th a t are not 
properly coated (and there are some in every batch), and therefore easily detected by 
the body’s reticulo-endothelial system, will be eliminated very quickly. This model 
helps to lessen that drop off by not taking the improperly coated nanoparticles into 
account as much as (2.3). An exponential decay function is used:
11
C B( t ) = a * e ~ 0*t , (2.4)
where a and 0  are real-valued param eters and t is time (in minutes). These parame­
ters were found in the same way as those for (2.3) while only using the experimental 
data  from the retention phase. As with the rational model, this yielded low error 
when compared to the experimental data. Figure 2.2 shows the exponential plot for 
the same mouse as depicted in Figure 2.1. It is also of interest to  find the area under










R-SquarecU 0.89122~  2.5
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1200 1400600 800 
time (minutes)
Figure 2.2: Approximated exponential curve found using R-squared (left) and TLS 
(right)
the curve (AUC) of each fit for each mouse as it can be telling of the to tal uptake of 
the nanoparticles in the body. W ith th a t in mind, while finding the best fit models, 
code was also run to find the maximum values for the rational fit, the area under the 
curve for both fits, and the half-life for the nanoparticle circulation in the bloodstream. 
Just as the uptake can be found using the area under the curve, the retention is seen 
by looking at the half-life [17]. The area under the curve was found using Simpson’s
12
quadrature with the best fit array and the half-life by finding the time a t which the 
absorbance is half tha t of the maximum value of the best-fit model.
2.2.4 A bsolu te V alue M odel
The rational model was useful in predictions but, though it yielded good R- 
squared values, was found to be skewed towards the elimination phase of the curve. 
That is, it took more time on average in the prediction models to reach the maximum 
absorbance than was actually being observed in experiments. In an attem pt to solve 
this problem, a new model was used th a t showed a sharper rise to help account more 
properly for the accumulation phase of the curve. This function has been found 
to yield similar R-squared values overall but showed a more realistic shape when 
compared to the experimental data. Several exponential values were tested before 
arriving at the equation:
CB(t) = -
2 3
a * t 3 —(3 + /?  +  7  *<4, (2.5)
with a,  j3, and 7  being real-valued parameters and t is time (in minutes). The 
constants are found in the same way as those of (2.5) and (2.4). Figure 2.3 shows a 
plot of this fit for the same mouse displayed in Figures 2.1 and 2.2.
2.2.5 P iecew ise M odel
In order to obtain a model th a t would have a still better fit for both the uptake 
and retention phases, a concatenation of functions to create a piecewise function was 
done. As it is the goal of this project to  be able to  create these models in real time, 
it was necessary at this point to use functions th a t had already been found to  yield a
13


















Figure 2.3: Approximated absolute value curve found using R-squared (left) and 
TLS (right)
good fit for either the uptake or retention phase. W ith th a t in mind, the exponential 
fit was used for the retention phase and different injection profiles were considered 
for the uptake.
Four injection profiles per dosage group are considered in this work. The first 
is linear, thus indicating a linear rate, the second is a positive quadratic, indicating an 
increase in the rate of injection as time progresses, the third is a negative quadratic, 
indicating a faster rate of injection initially th a t levels off toward the end of the 
injection time window, and the last is an exponential curve, indicating an exponential 
rate. The four injection profiles per dosage, denoted /*(£) with i =  1 ,2,3, 4, were 
designed to satisfy the same conditions as those specified for (2.4), thus yielding
h ( t )  =  (^)t  +  a,
h { t )  =  ( f ) ( t  +  v)2,
( 2 .6 )
h { t )  =  +  a,
I4(t) =  e ^ M - l ,
14
with q from (2.4), t is time, and 77 equal to the injection time (10 minutes or 0.1667 
hours unless otherwise specified). These profiles are shown for the average mouse 
in each data set ( lx  and 2x) in Figure 2.4 and are described further in Chapter 3. 











F ig u re  2.4: Injection Profiles for lx  Mouse (left) and 2x Mouse (right) (in OD)
the already found exponential function representing the retention phase. In order to  
have a more ideal control effort, the negative quadratic injection profile is used here 
yielding the equation
CB(t) =
■($)t2 + a  : 0 < t < t i
(2.7)
q  * e 4i) : t > ti
where a  and rj are the same as in (2.6). This gives the model shown in Figure 2.5. As 
this model is actually a concatenation of functions and is not found using a  minimal 
search algorithm, it is not necessary to compare the different error term s in this case. 
These error calculations have essentially already been found during the calculation of 
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Figure 2.5: Approximated piecewise curve 
2.3 R esu lts
There were several different models presented and each gave a different insight 
into how the experimental data  behaves in real time. The R-squared values for each 
model for each mouse were found using the residuals in the y-direction with the 
interpolation experimental data  points vs. the points found in each best fit model, as 
described in Subsection 2.2.1. These values are shown in Table 2.1.
When analyzing the mean and median shown in Table 2.1 we can see th a t the 
values for each model set are quite close with the exception of the piecewise models 
where the mean= .759 and the m edian= .915. This discrepancy most likely implies 
outliers in the data  set for th a t model which are assumed to  be caused by the weakness 
in the R-squared value. It is im portant to note th a t, since only the vertical values 
are considered in the R-squared calculation, some of th e  values may be quite low 
even though the figures show th a t model appears accurate. The vertical values were
16









20111104A-1 0.681 0.809 0.998 0 . 2 1 2
20120120C-3 0.499 0.861 0.867 0.947
2 0 1 1 1 2 0 2 A- 0 0.558 0.936 0.993 0.908
20120120C-5 0.559 0.862 0.972 0.771
20111104A-3 0.479 0.945 0.928 0.925
2 0 1 1 1 2 0 2 A- 1 0.438 0.933 0.972 0.892
20111202B-1 0.562 0.941 0.989 0.915
20111202A-2 0.734 0.704 0.919 0.276
20120120A-0 0.185 0.815 0.933 0.931
20111104B-1 0.819 0.672 0.984 0.132
20111104A-5 0.665 0.672 0.979 0.350
20111202B-3 0.802 0.652 0.992 0.639
20111104B-3 0.793 0.936 0.997 0.947
20111202B-2 0.711 0.853 0.991 0.987
20120120D-0 0.580 0.963 0.978 0.958
20120220A-3-5 0.563 0.920 0.983 0.979











considered as well in the TLS method (as discussed in Subsection 2.2.1) though using 
these considerations tended to produce very similar models as those found using the 
R-squared calculation. T hat being said, the mean and median values shown for the 
exponential models are considerably close to one, meaning that model is consistently 
accurate. It makes sense tha t this model shows the most accurate results as it only 
models the elimination phase when the injection phase appeared to be the main source 
of error for the other models. Due to the lower R-squared values for the models that 
show both the injection and elimination phases it can be assumed th a t the injection 
phase of the experiment is more difficult to predict than  the elimination phase. This 
is most likely because of the lack of experimental d a ta  points for this phase of the
17
experiment. The sparse data  collection during the injection forces the models to 
make more assumptions than are needed during the elimination phase where more 
data points were given. The absolute value model appears to be the most accurate 
model which takes both the injection and elimination phase into account. However, 
as discussed above, the piecewise model appears to  describe the da ta  accurately as 
well, with the exception of the few values in the da ta  set already discussed.
CHAPTER 3 
STATISTICAL EVALUATIONS
W ith the best fits found as described in Chapter 2 for each of the mice for 
each of the models, it is necessary to perform statistical evaluations to ensure first 
that the results make biological sense and also to make certain th a t averages of each 
data set can be taken. The Spearman Rank Correlation test, described in Section 3.1, 
was chosen to test how well certain values in the data  compared to  others which is 
descriptive of the raw data  found in the experiment. The Wilcoxon Signed Rank test 
described in Section 3.2 showed whether all of the least fits for a particular model 
could be averaged to create a “m aster mouse” w ithout loss of generality. The non- 
parametric tests were chosen due to the small da ta  sets and lack of normality within 
the sets [31]. The freeware program R was used for this analysis.
3.1 Spearm an R ank C orrelation
The first test run was the Spearman rank correlation in order to investigate 
how well certain values within the da ta  correlated. The results are shown in Table 3.1, 
with a p close to  ±  1 implying a high correlation. The value p is a nonparam etric 
measure of statistical dependance between any two variables. As can be seen in 
Table 3.1, almost none of the data  comparisons yielded high correlation coefficients.
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While these results are of interest to  the biological portion of the experiment, they 
do not have a negative effect on this analysis.
Table 3.1: Spearman Rank Correlation Results
D ata Sets Tested P
*max absorbance for lx  rational model vs. 
AUC for lx  rational model
0.2771084
*max absorbance for lx  abs. value model vs. 
AUC for lx  abs. value model
0.3012048
max absorbance for 2 x rational model vs. 
AUC for 2 x rational model
0.6727273
max absorbance for 2 x abs. value model vs. 
AUC for 2 x abs. value model
0.60
*AUC for lx  exp. model vs. 
AUC for lx  abs. value model
0.5421687
*AUC for lx  exp. model vs. 
AUC for lx  rational model
0.5421687
AUC for 2x exp. model vs. 
AUC for 2 x abs. value model
0.8545455
AUC for 2 x exp. model vs. 
AUC for 2 x rational model
0.8545455
The * in Table 3.1 implies th a t the exact p-value could not be computed with 
ties. As this warning came up when the test was run, it was appropriate to report it 
here. However, since the outcome of the test is dependent on p and not p, the fact th a t 
the p-value could not be computed on some of the tests is irrelevant. The first set of 
tests run evaluated the level of correlation between the maximum values calculated in 
the models and the AUC for the respective model. As the highest of these correlations 
found was 0.6727 it is clear th a t there exists no clear correlation between these values. 
This result is not what was expected as it would seem reasonable th a t the higher 
the maximum value of the model is, the higher the AUC would be as well. That
assumption, however, is not supported by this analysis.
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The second group of values (the bottom  four in Table 3.1) test the correlation 
between the AUC for the exponential models and the AUC for rational or absolute 
value models. Though the values for the lx  models are quite low, the 2x models 
seem to have a high correlation. It is unusual th a t the different initial dosages would 
produce such different results in this test but it is expected that the exponential model 
would have a good correlation with the other two. This analysis is taken into account 
in Chapters 4 and 5 in the discussion of the different controllers th a t are presented.
3.2 W ilcoxon  Signed R ank
The Wilcoxon Signed Rank Test was performed on each individual set of data, 
testing if the mean of the data is statistically equal to the median. The null hypothesis 
for the test on each da ta  set was th a t the median is equal to the mean, which would 
imply th a t the data is closely related with the alternative hypothesis being th a t mean 
and median are not equal, or th a t the da ta  is not closely related. The null hypothesis 
was rejected if the found p-value was less than a  (which was chosen to  be 0.05) and 
was accepted otherwise. The results of this test are quite significant as negative 
results would prevent the analysis from moving forward for th a t particular data  set. 
The results from this test are shown in Table 3.2 with * implying the same warning as 
was in Table 3.1. It is shown th a t the da ta  within each set are statistically similar as 
the p-value that was found was higher than the chosen a.  Though the exact p-value 
could not be determined for certain sets, the close calculation which was found was 
determined to be a good estimate. As the sets were all found to be statistically similar 
we are now able to average each set without concern of misrepresenting the data.
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Table 3.2: Wilcoxon Signed Rank Test Results
D ata Set Tested p-value
max absorbance for 2 x rational models
max absorbance for 2 x abs. value models
AUC for 2 x rational models
AUC for 2 x exponential models
AUC for 2x abs. value models
max absorbance for lx  rational models
max absorbance for lx  abs. value models
AUC for lx  rational models
AUC for lx  exponential models











3.3 C onfidence and P red ic tion  Intervals
As all of the mice within each individual da ta  set were found to  be statistically 
similar, an average of each data  set could be performed to create a “m aster mouse” 
of all of the models. W ith these “m aster mice” , confidence and prediction intervals 
were calculated using MATLAB®.
The difference between confidence and prediction intervals is an im portant 
distinction to make. As an example, an 80% confidence interval implies th a t if 100 
similar samples were drawn, in 80 out of 1 0 0  tests, the mean absorbance measure 
would fall in th a t interval. The confidence interval is a good indication of how well 
the mean of the data  has been determined. A prediction interval gives a range of 
where the next data point sampled can be expected. T hat is, for example, for an 85% 
prediction interval, there is an 85% probability th a t the next sampled data  point will 
fall within th a t range. This interval tells about the distribution of the data, rather 
than the uncertainty in determining the mean [2], [24].
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The confidence intervals were calculated at 80% and 90% for each d a ta  set. 
To find these intervals within each set, the absorption values a t each time point were 
first averaged in order to create the m aster mouse for th a t d a ta  set. The standard 
deviation was then found using the built in MATLAB® function. For the lx  data 
sets, the 80% intervals were calculated at each time point by taking the average 
absorbance ±  1.383 x standard deviation and the 90% bounds by average absorbance 
±  1.833 xstandard deviation. And for the 2x data sets: 80% bounds by average 
absorbance ±  1.415*standard deviation, 90% by average absorbance ±  1.895*stan- 
dard deviation. Each of these values were found in the standard t-distribution table 
according to the number of mice in each data  set.
The prediction intervals for each data  set were calculated a t 85% for each time 
value so th a t a mostly smooth function was created for the upper and lower bounds 
of the intervals. In order to calculate the intervals, the absorbance values for each 
time set first had to be arranged in increasing order. Once the data  was in increasing 
order, the central 85% of the data  was taken to  be the prediction set for th a t time 
point.
For ease of comparison, the exponential models with their confidence and 
prediction intervals are shown in Figure 3.1. Figure 3.2 shows the lx  and 2x rational 
models with their respective confidence and prediction intervals, found in the same 
manner as the exponential intervals. Similarly found were the absolute value models 
for the lx  and 2x data sets, shown in Figure 3.3 and the piecewise models shown in 
Figure 3.4. The intervals for these figures are shown with 90% confidence intervals 
being the outer dashed lines and the 80% confidence intervals being the inner dotted
23
line. The 85% prediction intervals are represented by the two solid lines surrounding 
the center line (with the center line being the model itself).
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Figure 3.1: Exponential lx  Model (left), Exponential 2x Model (right)
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Figure 3.2: Rational lx  Model (left), Rational 2x Model (right)
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F ig u re  3.3: Abs. Value lx  Model (left), Abs. Value 2x Model (right)
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F ig u re  3.4: Piecewise lx  Model (left), Piecewise 2x Model (right)
The prediction intervals are different from the confidence intervals as they give 
a range of where the next experimental data  point should fall as opposed to where 
the mean of future data  sets would fall. The fact th a t the different intervals are close 
in value is a good indication the experimental da ta  sets are closely related. Each of 
these intervals can be useful for the identification of untoward reactions when applied 
in an experimental setting by comparing data  points measured in real time with the 
‘Master Mouse’ for the respective dosage and its confidence and prediction intervals.
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D ata points falling outside of these intervals would be a flag for further investigation 
to determine untoward reactions and /o r to change to  dosage scheme accordingly.
CHAPTER 4
LQR TRACKING CONTROL
As the least error m athem atical models have been found in Chapter 2 and 
confirmed through the statistical evaluations in Chapter 3, we will now show how the 
exponential model is utilized in a sta te  space feedback control framework to regulate 
the nanoparticles in the bloodstream. An equal time delay is also introduced in both 
the state and control input for the purpose of studying the  alternate dosing strategies 
shown in (2.6). While only the exponential model is being controlled, the inclusion 
of the dosing strategies to account for the time delay creates a piecewise function 
which is identical to the piecewise function described in Chapter 2.
Clearly, (2.4) is the solution to  the simple first order, linear ordinary differential 
equation
C B{t) = - 0  C B(t), (4.1)
where Cs{t)  =  -—7 --  , Cb(£ =  0) =  7 G IR in (2.4), — 0  G IR is the exponential 
at
decay rate, and time t =  0  corresponds to the time when the nanoparticles are at 
their highest concentration in the bloodstream, which occurs a t some delayed time 
after the nanoparticle injection. The two specific quantities of interest for comparison 
between the experimental da ta  and the model are the nanoparticle half-life and the 
AUC, referring to area under the bloodstream nanoparticle concentration curve. The
26
half-life can be used to quantify nanoparticle retention, or how long the nanoparticles 
remain in the body. The area under the curve is im portant because it describes the 
total uptake of nanoparticles by the body. Table 4.1 shows a comparison between the 
experimental data  and the model for these two quantities of interest with an * implying 
irrelevant results due to unrefined data, meaning th a t the set of experimental da ta  
points did not provide enough information to appropriately calculate the AUC. W ith












1 / 2 -life
(min)
Exper. 
1 / 2 -life 
(min)
20111104A-1 1 .0 0 2163 1981 507 488
20120120C-3 0.87 2725 2446 505 444
2 0 1 1 1 2 0 2 A- 0 0.99 1978 1747 465 499
20120120C-5 0.97 2916 2628 562 533
20111104A-3 0.93 1982 1828 305 347
2 0 1 1 1 2 0 2 A- 1 0.97 1931 1716 409 444
20111202B-1 0.99 2088 1851 349 350
20111202A-2 0.92 1769 1480 349 248
20120120A-0 0.93 2553 2300 496 444
20111104B-1 0.98 1 1 0 0 743 339 365
20111104A-5 0.98 1880 1609 356 367
20111202B-3 0.99 964 701 234 247
20111104B-3 1 .0 0 961 773 177 205
20111202B-2 1 .0 0 915 * 283 272
20120120D-0 0.98 1815 1610 276 309
20120220A-3-5 0.98 1521 1 2 1 2 326 330
20120220A-5 0.98 1206 1024 282 304
mean 0.97 1792 1603 366 370
median 0.98 1978 1788 349 350
the mean and median for each data  set shown in Table 4.1 being close together we 
can assume that the data within each set do not have any extraneous values throwing 
off the set as a whole. The controller presented later in this chapter and also those 
presented in Chapter 5 aim to maximize the AUC and also lengthen the half life of
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the mouse (increasing the AUC and lengthening the half-life would theoretically go 
hand in hand). After the half-life and area under the curve results were found for 
each mouse, statistical tests for similarity and correlations were run as described in 
Chapter 3.
Because it is of interest to investigate different injection rates, the rate effects 
on nanoparticle bioavailability, and maintaining the bloodstream nanoparticle con­
centration within an established therapeutic window, (4.1) is posed as a controlled, 
delay differential equation (DDE). Specifically of interest is the optim al control of the 
system with equal delays in both the state and control input. The general theory for 
the LQR control problem related to delay systems can be found in [6 ], [8 ], [13], [35], 
[36]. The model and control frameworks presented here will follow the more recent 
formulation presented in [7]. The system of interest is given by
CB(t) = ~ P C B{t - h ) +  bu(t -  h ), (4.2)
subject to the history function C B(s) = 4>(s) G C({—h, 0]; IR1) for all s G [—h, 0], 
where h is the time delay in hours, C B(t) G IR1 is the system sta te  representing 
concentration of nanoparticles in the bloodstream, u(t) G IR1 is the control input, 
6 is a real-valued constant control input multiplier, and — (3 G IR is the exponential 
decay rate. W ith the inclusion of a delay in the  state, (4.2) is an infinite-dimensional 
system (see, for example, [25]). This means th a t the function space has a basis set 
which is infinite which further means th a t the function cannot be represented using a 
finite set of simpler functions. From a practical standpoint, note th a t the time delay, 
h, will correspond to the length of tim e over which the nanoparticle injection is given,
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and different history functions (p(s) (the same as those functions given in (2 .6 )) will 
correspond to the different injection profiles being considered.
4.1 C ontrol S trateg ies
W ith (4.2) being a linear system, standard linear quadratic control techniques 
will be employed. The solution to this control problem, with equal tim e delays found 
in both the state and input, is found in [7] and summarized here, with appropriate 
modifications made to include tracking, similar to the derivation in [16]. The specific 
control objective of interest includes output tracking, for the purpose of regulating the 
bloodstream nanoparticle concentration to lie within a specified therapeutic window. 
This will be analyzed for multiple injection profiles, i.e. rates.
In considering a general linear system with tim e delay
with the usual assumptions as described in [7], the control implementation involves 
a Linear Quadratic Regulator (LQR) state tracking design, where the quadratic cost 
function to be minimized is
and the tracking problem reduces to  a disturbance-rejection problem of the form
(4.3)




where xi(t)  =  x(t  — h) = £(f — h) — £(t — h ), ui(t)  =  u(t  — h), w(t)  is represented by
w(t)  =  |  ^  0, (4.6)
f  is the state of some original dynamical linear system of interest,
i ( t )  = A 0(t)€(t -  h) +  B 0(t)u(t -  h) + z, (4.7)
£ is the known desired state target of (4.7), and 2  is zero-mean, Gaussian, white noise. 
The Hamiltonian for the optimal control problem (4.4), (4.5) is defined as 
H ( x , u , q . t ) =  ~uT R( t )u + ^ x T L(t)x
(4.8)
+qT [A(t)xi + B( t )ui  +  w\.
For the purpose of minimizing the Hamiltonian with respect to  u, the gradient of
(4.8) is set equal to zero. Then solving for u yields the optimal control
u* = - R r \ t ) M T{t)BT{t)q(t), (4.9)
du (f 1
where M(t)  := ——̂—. Selecting a general quadratic form 
du
J*(x, t) = ^-xT (t)Q(t)x(t)  + bT(t)x(t)  +  c(t) (4-10)
for the solution to the Hamilton-Jacobi optimization equation, to account for the
disturbance term w(t),  yields the co-state
8 J*(x t)
Q(t) = -  =  ~Q(t )x( t )  -  b{t). (4.11)
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Then, with arguments of variables om itted from this point forward in the derivation 
for conciseness, the Hamilton-Jacobi optimization equation becomes
1 i.T„ x ____ j  , L,T;-x Qx — b x  — c = min < - x  Lx  + - u  Ru  
2 u I 2 2
+(•—Qx — b)T(Ax\  +  B ti\ +  >
thereby yielding the optimal control
(4.12)
u* = R - ' M 1 B 1 (Qx + b). (4.13)
Therefore, values for Q , M, and b must be determined. To determine Q, consider the
. dq{t) d H  , . , u
co-state equation —;— =  —-r—, which yields 
at ox
Qx + Qx + b = Lx  + A  M i q , (4-14)
Qx i
where Mi :=  ——. Now substituting (4.11), (4.5), and then (4.13) into (4.14) yields 
ox
Qx  +  QAx( t  - h )  + Q B ( R ~ l M TB TQx + R~lM TB Tb)
(4.15)
+Qw + b = L x -  A TM l Qx  -  A TM 1b.
Differentiating (4.15) with respect to x  and simplifying because M  is the identity
m atrix per the argument in [7] produces the quasi-Riccati equation
Q = - Q M XA  -  Q B R ~ l B TQ + L -  A t M 1Q, (4.16)
where M x =  0 for t G [0, h) and Mi =  /  for t > h, per [7]. Note th a t while the co-state 
selected in this work differs from th a t in [7], to accommodate for a  control tracking 
objective here, the arguments to determine the values of M  and M\  are identical. 
To determine b, the optimal control (4.13) is substituted into the Hamilton-Jacobi 
equation optimization (4.12) and different powers of x  are equated to obtain
b = [ A  + B R ~ 1B TQ}Tb + Qw.  (4.17)
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Note th a t the solution for c in (4.10) is irrelevant for the control design sought here, 
and thus, the differential equation is not shown. Because of the boundary conditions 
J*(x, T) = ^ [ x ( T ) ] t i / j [x(T)]  for all x,  there also exist the boundary conditions Q ( T ) = 
—ip and b(T) =  0. After the computation of Q  and b, the optimal control law is w ritten 
as
u* = R - l B TQ { ^ - i )  + R ~ 1B Tb, (4.18)
which is then implemented in (4.5).
4.2 N um erical R esu lts
The numerical results presented here correspond to each of the ‘M aster Mice’ 
presented in Chapter 3. This is because it is desired to consider the predictability of 
nanoparticle bioavailability for individual ‘patients’ and, therefore, predicting for the 
average mice is the most appropriate way to test the method. The param eters of best 
fit for (4.1) were determined to  be
7  -  (3.2475,4.1573), /? =  (0.135, 0.095), (4.19)
for the respective lx  and 2 x models following an injection th a t began ten  minutes 
earlier with the injection profiles described in (2.6). Because gold nanoparticles are 
devices, as opposed to medications, and only activated through laser, there is no 
maximum nanoparticle level for a patient. However, because it is desired to  expand 
this analysis to many drugs and treatm ents, it is im portant to minimize the excess 
dosages of the nanoparticles. It also efficient from an industrial point of view to
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limit the total dose as nanoparticles do cost money to  create. Also, the system is 
not controlled on the time interval (0,0.1667) hours, so the area under the control 
curve is only computed on [0.1667,20] hours. It was decided to end the model at 
2 0  hours as the absorbance value has dropped below functional levels by th a t time. 
The controller plots for each of the injection profiles can be found in Figures 4.1 and
4.2 for the lx  and 2x ‘Master Mice’, respectively. The plots show no distinguishable 











































F ig u re  4.1: Controllers u(t): Corresponding to: / l i ( f )  (upper left), (upper
right), / 1 3 (f) (lower left), / 1 4 (f) (lower right),
To calculate the control effort required to  achieve each of the injection profiles 
and steer the bloodstream nanoparticle concentration to .5*maxiinum absorbance over 














































F ig u re  4.2: Controllers u(t): Corresponding to: I 2 i(t) (upper left), I 2 2(t) (upper 
right), / 2 3(f) (lower left), / 2 4 (f) (lower right),
curve u(t) is added to the area under the corresponding injection profile curve. These 
results are found in Table 4.2. The required control effort is quite similar for each of 
the injection profiles, with the positive quadratic rate requiring the least amount of 
nanoparticles for each dosage group. Note th a t for all t, the control effort required 
for the various profiles follows the order I2 < I 4 < I\ < I3 for each dosage group. 
However, for t G [—0.1667, 0], the control effort required for / 3 is the largest of all the 
injections for each dosage group while for t G [0.1667, 20], the control effort for / 3 is 
the smallest of all the injection profiles. It appears th a t the negative quadratic rate 
of injection found through using the / 3 profile allows the bloodstream nanoparticle 
concentration to “build up” so th a t fewer nanoparticles are needed later to achieve
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the desired target, thus providing for a more efficient use of resources. I\  follows
a similar pattern for each dosage group and therefore also appears to provide for a
more efficient injection. Given these results, it was determined th a t using the negative 
T ab le  4.2: Control Efforts for Corresponding Injection Profiles (OD)
Injection t e  [-0.1667,0] t € [0.1667,20] Total Effort
I h ( t ) 0.2707 64.3755 64.6462
I h ( t ) 0.1805 64.4558 64.6363
I h ( t ) 0.3609 64.2951 64.6560
i u ( t ) 0.2076 64.4321 64.6397
/ 2 i(f) 0.3465 97.2718 97.6183
/ 2 2(<) 0.2310 97.3561 97.5871
/ 2 3 ( 0 0.4620 97.1875 97.6495
I24(t) 0.2558 97.3386 97.5944
quadratic injection profile is the most efficient. Using this injection, (4.2) was plotted 
and shown in Figures 4.3 and 4.4 with their respective uncontrolled models for ease 
of comparison.












F ig u re  4.3: Controlled lx  Model (left), Uncontrolled lx  Model (right)
4 .3  D o sag e  C o n v e rs io n
These models control the absorbance level (in OD) of the nanoparticles over 
time but it is necessary to convert the values from the measurement to  /uL else, as
36















F ig u re  4.4: Controlled 2x Model (left), Uncontrolled 2x Model (right)
injections are measured in fiL and not OD, the results are not useful in a real time 
experiment. In order to accomplish this, the peak absorbance values from the lx  
and 2x ‘Master Mice’ along with the /jL injected were plotted and different functions 
were fitted to the plot. The exponential function (4.20) was found to be the most 
reasonable:
f ( x )  =  0.6533x°'3564, (4.20)
where f ( x ) =absorbance in OD and x  =am ount injected in y L. Inversely (4.21)
f ( y )  =  3.3019z/2'8058, (4.21)
gives the opposite conversion where f ( y )  =  amount injected in //L and y =aborbance 
value in OD. These equations yield values consistent with what is expected exper­
imentally as the absorbance value rises quickly with the initial injection and then
begins to level off over time. A sample table of points is given in Table 4.3 and the
plot of (4.21) is given in Figure 4.5.
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F ig u re  4.5: OD to  /xL Conversion 
T ab le  4.3: Sample Values using the OD to  /xL Conversions
£fL injected Resultant absorbance (OD)
0 0.6533
90 ( lx  dose) 3.2475
180 ( 2 x dose) 4.1575
360 ( 4x dose) 5.3233
720 ( 8 x dose) 6.8150
Using (4.21), the total amount of /xL needed to maintain the controller in the 
model given in (4.2) was calculated and those values are given in Table 4.4 along 
with the amounts used in experiments for the purpose of comparison. These values 
were determined by first converting the absorbance values from OD to /xL for both 
the controlled and uncontrolled models, then summing the difference between the 
controlled and uncontrolled models of the converted values. The injection was found 
this way because, as the uncontrolled model gives the absorbance values when no 
injection (outside of the initial bolus injection) is made, the converted values from 
the uncontrolled model need to be subtracted from the calculation to ensure that
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only the actual injection amount necessary in the controlled model is found. We are 
basically finding the area between the pL curves for the controlled and uncontrolled 
models.
T ab le  4.4: pL of Nanoparticles Required per Model
initial target uncontrolled model controlled model
absorbance (OD) absorbance (OD) to tal dose (/rL) to ta l dose (fiL)
3.2475 1.6238 90 234.64
4.1573 2.0789 180 1080.92
The values in Table 4.4 reveal th a t using this method with the same initial 
injection as is used in the uncontrolled model we see th a t the controller requires quite 
a  bit more fih to be injected than is ideal. However, as the absorbance level was kept 
a t an ideal point with this method, it is worth investigating further to  a ttem pt to 
lower the overall control effort and, therefore, lower the necessary injection amount.
CHAPTER 5
CONTROLLER ANALYSIS
Because, in an experimental setting, each patient will have different reactions 
to a treatm ent and will need to  be treated accordingly, it is im portant to  investigate 
several different control strategies. This will provide more tools th a t can be called 
upon when this analysis is applied in real-time in an experimental setting. Using 
different strategies also helps to analyze the efficacy of any specific controller.
5.1 Further Investigation  in th e LQ R C ontroller
Since the controller presented in Chapter 4 tracked efficiently, it was also of 
interest to consider a lower initial injection so th a t the to tal injection over time could 
be kept to minimum. Though it is unlikely th a t the amount of gold nanoparticles 
could ever build to a lethal level, it is im portant to look ahead to other treatm ents 
that may be able to be used with this analysis. Minimizing the injected amount 
needed will also help to reduce cost of treatm ent regardless of the treatm ent being 
used. W ith this in mind, each model was also run with an initial injection set to  half 
of the original maximum absorbance of the respective models. T ha t is, as the goal 
of the controller is to track to half the maximum absorbance, these models are now 
trying to track to the initial injection value. These plots are shown Figures 5.1 and
5.2 with their respective uncontrolled models. These models show th a t the applied
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controller is able to  to maintain the absorbance level of the nanoparticles a t a  level 
which is more acceptable than the uncontrolled models. As the LQR controller is 
designed to run in an optimal time frame, it is encouraging th a t the controller has an 













Figure 5.1: Controlled lx  Model (left), Uncontrolled lx  Model (right)
















Figure 5.2: Controlled 2x Model (left), Uncontrolled 2x Model (right)
are presented in Table 5.1 along with those from the controller shown in C hapter 4 
for ease of comparison. The dosages are found using the same process as th a t for 
the controller described in Chapter 4. The injections over time are shown in Figure 
5.3. The values presented in Table 5.1 show th a t using a lower initial dose gives a
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F ig u re  5.3: Controlled lx  Model (left) and 2x Model (right), in n L 
T ab le  5.1: Total Dose of Each Control Strategy
lx 2 x half lx half 2 x
initial 
absorbance (OD) 3.2475 4.1573 1.6238 2.0789
target 
absorbance (OD) 1.6238 2.0789 1.6238 2.0789
LQR control 
total dose (fiL) 234.64 1080.92 65.25 299.1
significantly more efficient method of control in terms of total injection. For the 2x 
model, the percent error between the controlled model and the tracking target is only 
18.53%. However, for the lx  model, the calculated percent error is 50.15%. The low 
percent error for the 2 x model is promising but the high error for the lx  model shows 
th a t this method may not be reliable when many different dosage groups are being 
considered. A model which requires a  slightly higher overall injection but consistently 
keeps the absorbance closer to the tracking target may be preferred. Of course, too 
high of an overall injection is not ideal either.
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5.2 A nalysis o f  ‘C on tro l’ U sin g  D irac D elta  Functions
Though the controller discussed in Section 4.1 is interesting mathematically, it 
can not be easily replicated in a real time experiment with mice (which is im portant to 
realize as animal testing must be performed to  confirm results before human testing 
can take place), mainly because the controller is a continuous feedback controller 
rather than a discrete controller. A discrete controller may also be useful in human 
testing as it may be simpler to detect untoward reactions with this type of control 
strategy than it would be with a continuous time control. W ith the injection not 
happening continuously, any untoward reaction would also be minimized when using 
this strategy. For these reasons, a good next step was to control the exponential 
function described in (4.1) using several Dirac delta functions to m athem atically 
replicate bolus injections given at different tim e intervals. This equation is similar to 
(4.1) and is given by
Cs{t) — — 0Cs{t )  +  m\5( t  — h) + m2<5(f — 2 h) + m^8{t — 3 h)
(5.1)
+ m 4(5(t — Ah) +  m^8(t  — 5 h) +  m(,8{t — 6h),
where Cb {1) =  =  0) =  7  G IR in (4.1), — {3 e  IR is the exponential
decay rate, h is the time delay for the injections in hours, and m* corresponds to the 
magnitude of the corresponding injection (represented by the Dirac delta functions) 
and is measured initially in OD and then converted to  /iL. m i, m 2, m3, m 4, m 5, ra6, 
and h were found by minimizing the TLS error that is calculated by comparing the 
solution to (5.1) against a constant function which was set equal to  half the maximum 
value (which is considered to be in the therapeutic window for the nanoparticles),
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following the examples in [21]. Finding these param eters proved to  be more difficult 
than using the search algorithm described for the models in C hapter 2. First, (5.1) 
was solved analytically with a differential solver in MATLAB® and then evaluated 
using different values for each unknown param eter until a minimum error was found. 
The resulting plots over time are shown in Figures 5.4 and 5.5 for the lx  and 2x 
models, respectively. These plots show th a t several discrete injections are capable 
(for both the lx  and 2 x models) of m aintaining the absorbance value (in OD) at a 
level which would be considered within the therapeutic window of treatm ent for much 
of the experimental time frame.





Figure 5.4: lx  Exponential Decay with Dirac Delta Functions
Table 5.2 shows the time between each injection given and the am ount per 
injection. It was decided to  limit the number of injections to six plus the initial 
injection. This was done for the purpose of feasibility in a real world setting. Of 
course, infinitely many injections would provide practically no error but th a t is not
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F ig u re  5.5: 2x Exponential Decay with Dirac Delta Functions
currently experimentally replicable. The time between injections was also restricted 
to be a constant value instead of varied. Tests were run with variable times between 
injections but these (much like having more injections) showed to  take longer to  run 
than would be reasonable in a real world setting. Having variable tim e steps, despite 
the longer time, did not provide significantly more effective ‘control’ of the exponential 
decay when compared to the constant time step. In the case of Dirac delta functions, 
the total injection amount is a simple sum of the each individual injection as this is not 
a continuous time controller. It is obvious from the values found in this analysis that 
having multiple smaller injections should provide a more efficient m ethod of keeping 
the nanoparticle concentration within the assumed therapeutic window and would 
theoretically require a smaller injection amount overall than the original m ethod of 
only one injection. When comparing the values from Tables 4.4 and 5.2 it seems clear
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Table 5.2: Results Using Dirac Delta Functions
Time between injections 1.053hrs 0.567hrs
Initial Injection 
2nd Injection (mi) 
3rd Injection (m2 ) 
4th Injection (m3 ) 
5th Injection ^ 4 ) 
















Total Injection Amount 66.069/iL 115.802/xL
Experimental Injection 45.0/iL 90.0/iL
that the use of the Dirac delta functions as opposed to one continuous time controller 
is a more efficient choice in terms to tal amount of /iL of nanoparticles needed.
5.3 P ID  Tracking C ontrol o f  th e  E xp on en tia l D ecay
The controller presented in Chapter 4 was determined to be appropriate for the 
given model. However, it was also of interest to  investigate the use of a PID tracking 
control as it is a common control strategy used in the engineering and industrial 
settings [19]. W ith a PID tracking control like the one presented in [33] we can 
evaluate the possibility of tracking the model to  a specific absorbtion value and also 
limiting the area under the curve so th a t the to tal injection is kept to a  minimum. 
The model to  be controlled is the same as th a t in C hapter 4 and given by (4.1).
5.3.1 Setup o f th e  P ID  C ontroller
For this controller, the delay is only included in the control function and the 
model (in the time domain) is then generally presented as
x(t) = A( t )x( t )  + B( t )u( t  — d ), (5-2)
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where d represents the time delay. Unlike the LQR controller presented in 4.1, the PID 
controller utilizes three different gains, kp, kt1 and kd which represent the proportional 
gain, integral gain, and derivative gain, respectively. The control function u in the 
time domain is given by
where kp, kr, and kd are the gains to be found later and e(t) is measured reference 
error time signal given as e(t) r — y with r  being the target output and y  the actual 
output. Each gain has a  different purpose within the control setting, as discussed in
[19]. The proportional control, kp, is used when the action of the  controller needs to 
be proportional to the magnitude of the error signal, e(t). The integral control, ki, is 
used in order for the controller to correct for any steady offset from a reference signal 
value. The derivative control, kd, uses the rate of change of the error signal, e(t), to 
increase the overall control effort.
Solving this problem in the time domain is overly complex; however the use 
of a Laplace transform into the frequency domain converts (5.2) into an algebraic 
equation, such as in [4]. As (5.2) and (5.3) are linear combinations of functions (even 
though those functions are not necessarily linear) and thanks to the linearity property 
of the Laplace transform (as described in [4]), the transform of each of these equations 
is equivalent to linear combination of transforms. T hat is, the transform  of a linear 




Solving for X  (s). (5.4) is represented by
(5-5)
with A: =  —j ,  L =  d, and T  =  — U. .4 < 0, &,T > 0 ensures th a t the problem is 
open loop stable by the theorems set forth in [33] and can therefore be solved using 
the described methods in the text. U (s) is found by transforming (5.3) yielding
U(s) = kpE(s)  +  k i E ( s ) -  +  kdsE(s)] (5.6)
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therefore the control transfer function is given by
C(s) = ^ \  = kp + ^ +  kds , (5.7)
E(s)  s
which is now an algebraic equation and not an integro-differential equation. Using 
the Laplace transform has also taken the delay term  in (5.2) and transformed it to 
an exponential decay in (5.4).
5.3.2 S tabilization  o f  P ID  Param eters
Following a main result in [33], we know th a t the range of kp values for which 
the open-loop stable problem can be stabilized using a PID controller is given by the 
condition
i i  Tt  1
(5.8)1 , 1 
~ k < k ’ < k
T
—a sin (a )  — cos(a)
Lj
where a  satisfies the equation
T
tan (a ) =  -  (5.9)
48
with the restriction a  £ (0, 7r); a  is found using the Bisection m ethod in this work. 
These values of kp are then used in
T
kkp +  cos(z) — —z  sin(z) =  0. (5.10)
where the value 2  is also found using the bisection method. As there is a  range of 
possible values of kp, it stands to reason th a t there are also many solutions to  (5.10). 
These solutions, z j , are then used in
f 1 12
r  t  i  ( 5 ' n )sin (zj) +  —Zj cos (zj)
Lj
bj (z j )  =  L
kzj
with distinct solutions being found for each solution of (5.10). W ith these values, we 
now have all the necessary information to determine the conditions for the stabilizing 
regions ki and kd- For all whole number values of j  where j  £ [l,length(fcp)], these 
conditions are given by
ki >  0
kd > m- j ki +bj , (5.12) 
kd < m 2jki  +  b2j
The following algorithm was coded in MATLAB® to  find each set of possible values 
and is given in [33].
1. Initialize kp = — £ and step =  77^ ;,  where N  is the desired number of points;
2. Increase kp as follows: kp +  step (this was done using a while-loop);
3. If kp <  ku then go to step 4. Else, term inate the algorithm;
4. Find the roots zx and z2 of (5.10);
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5. Compute the parameters rrij and bJ: j  =  1,2 associated with the previously 
found Zj by using (5.11);
6 . Determine the stabilizing region in the ki — kd space using (5.12);
7. Go to step 2 ;
Following these conditions creates different trapezoidal or triangular shaped planes 
for each value of kp. These planes are shown in Figure 5.6 for the system under 
consideration here.
A r» » o f S ttO z t to n  Aiwe ef 8 W * z e M n
F ig u re  5.6: Areas of Stabilization for the lx  model (left) and 2x model (right)
5.3.3 R e su lts  U sing  th e  P ID  C o n tro l
W ithin the areas of stabilization shown in Figure 5.6, all values of kp, kx, and kd 
will provide a solution of (5.2) and (5.3); this means th a t, since the param eters are real 
values, there are as many solutions as there are combinations of the parameters. To 
be certain th a t a solution of minimal error was found, each combination of param eters 
was considered and the overshoot (in regards to the target of the tracking control) 
was found. Also, the norm of the difference of each solution vector and the tracking 
target was calculated. Each solution was first found by solving (5.5) in the frequency
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domain and then performing a numerical inverse Laplace transform using the code 
found in [3], which then provides the solution to (5.2) and (5.3) in the time domain. 
The overshoot, plotted against the respective function’s kt and kp values is shown 
in Figure 5.7. This figure shows the wide range of overshoot values th a t are found 
when each combination of param eters is considered. The average overshoot for each 
model is on the magnitude of a t least 1 0 14 meaning th a t the choice of param eters is 
of utmost importance when using this control design.
Overshool vs. k and k. Overshoot vs. k and kp i  p i
* to ’* x 10’5
6 > 2 -.
5-
1.5-
F ig u re  5.7: Overshoot for lx  (left) and 2 x (right) models
The solution sets utilizing of ku kp, and kd th a t provided the lowest norm 
calculation were considered desirable and are plotted in Figures 5.8 and 5.9. The 
solution set with the lowest norm was chosen in an effort minimize the stabilizing 
time of the model and that with the lowest overshoot was chosen in an effort to 
minimize the overall required injection. The values in the solution set were then 
converted from OD to fj,L using (4.21) and plotted in Figures 5.10 and 5.11. It would 
also be considered appropriate to use the overshoot as the performance criteria for 
this controller because it is desired to limit the to ta l injection amount while still
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tracking the absorbance to a desired value and limiting the overshoot accomplishes 
this. However, limiting the overshoot will not necessarily lessen the stabilizing time of 
the model and therefore may not allow the nanoparticles to build in the bloodstream.
The plots shown in Figures 5.8 and 5.9 show th a t the controller tracks to the 
desired value within the time frame of the experiment and with the initial absorbance 
value of 0 OD. The initial absorbance value for this controller is set to zero in order 
to more closely follow the examples given in the literature. However, because the 
initial absorbance value will typically be zero in an experimental setting, this is an 
appropriate condition to follow. There is also very little oscillation in the plots shown 
in Figures 5.8 and 5.9 and it stabilizes to  the target very quickly. W ith the absorbance 
values initially being below the target (unlike past strategies), it is likely th a t the level 
of required injection would be lower when compared to the other strategies.
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F ig u re  5.8: Controlled lx  with min norm (left) and with min overshoot (right) (OD), 
varied axes
While the models that give the minimum norm calculation do not necessarily 
show a faster stabilizing time than those with the minimum overshoot, they do show 
quick stabilizing times and are an appropriate way to guarantee a minimal (if not
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F ig u re  5.9: Controlled 2x with min norm (left) and with min overshoot (right) (OD), 
varied axes
the most minimal) stabilizing time when used with future models. Calculating the 
injection over time for these models was a two part process: the first to account for the 
injections made before the model stabilizes and the second is for the tim e following 
the stabilization of the model (when measured in OD). For the first portion of the 
calculation, the injection was found using the conversion given by (4.21) with the 
absorbance value at each time point. The injection am ount necessary to build to the 
absorbance at any one time point is then equal to difference between /iL at th a t time 
point and the //L at the preceding time point. Once the controlled model stabilizes 
to the tracking target, this method to find the injection amount is no longer useful as 
the difference in n L between one time point and the next would be very close to zero 
and, therefore, not an accurate description of the nanoparticles needed to maintain 
the absorbance at a particular value. For this reason, once the model reaches the 
point of stabilization, the amount of nanoparticles needed is found in the same way 
as it is for the LQR controller. That is, we are basically finding the area between 
the /rL curves for the controlled and uncontrolled models, where the uncontrolled
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model is the exponential decay function given by (2.4) with an initial value equal to 
the tracking target and a horizontal translation to account for the time taken for the 
model to stabilize to that target. The values found are shown in Figures 5.10 and 
5.11 and the total injection amounts are given in Table 5.3.













F ig u re  5.10: Controlled lx  with min norm (left) and with min overshoot (right)
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F ig u re  5.11: Controlled 2x with min norm (left) and with min overshoot (right)
w
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5.4 C om parison o f  th e  M eth od s o f  C ontrol
Aside from simply comparing the plots produced by each m ethod of control, 
the only way to properly compare the models is to compare the to tal error for each 
model (which is found using the Total Least Squares method in [30]) along with the 
required overall dose (in /iL) for each model. Each of those values was found and 
given in Tables 5.3 and 5.4, respectively. Judging by the error alone, it would seem
Table 5.3: Total Dose of Each Control Strategy
lx 2 x half lx half 2 x
initial 
absorbance (OD) 3.2475 4.1573 1.6238 2.0789
target 
absorbance (OD) 1.6238 2.0789 1.6238 2.0789
LQR control 
total dose (/iL) 234.64 1080.92 65.25 299.1
Dirac delta 
to tal dose (/iL) 127.3 235.33 66.07 115.08
PID control(w/0 initial OD) 
total dose (/iL) *
w /m in norm 





Table 5.4: Total Error According to Initial Absorbance
Initial /  Target No PID Control PID Control
Absorbance (OD) Control w /m in w /m in
overshoot norm
0 /  1.6238 * 2.4529 0.2957
0 /  2.0789 * 0.3820 0.5666
LQR Dirac
Control delta
3.2475 /  1.6238 430.81 178.47 285.73
4.1573 /  2.0789 472.66 539.72 432.52
1.6238 /  1.6238 572.93 140.89 39.44
2.0789 /  2.0789 695.07 26.53 105.9
that the PID control (whether by using the minimum overshoot or the minimum
norm) is the most efficient. However, because of the methods involved in stabilizing
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the PID controller, it requires several minutes to  hours to  run; as opposed to the other 
strategies which require seconds to minutes. The PID controller also requires a rather 
high total dose which is expected as it is the only m ethod of control analyzed th a t 
held the absorbance level to the desired target. This is not ideal when future work is 
considered as we would want to apply the controller during a real-time experiment. 
W ith this being said, it would appear using Dirac delta functions as the m ethod of 
control is the most efficient as it provides low error and a low to tal injection. This 
method is also able to keep the absorbance level close to  the target for the bulk of the 
experiment (as can be seen in Figures 5.4 and 5.5) and should be easily replicable in 
an experimental setting with some animals when a continuous infusion is not possible. 
When a continuous infusion is a possibility, the LQR control strategy is an efficient 
choice as well.
CHAPTER 6 
CONCLUSIONS AND FUTURE WORK
6.1 Sum m ary and C onclusions
In this work, several different models are presented to represent the  nanopar­
ticle concentration in the bloodstream over time via absorbance measurements. The 
algebraic model is described in (2.3) and plotted for the particular mouse in Figure 
2.1. Though it was a good starting point, this model was found to have a low R- 
squared value for each mouse modeled. It was determined that, overall, this model 
skewed the time of maximum absorbance to a later tim e point; it also tended to  yield 
low maximum absorbance predictions. For those reasons, a new model was used.
The absolute value model described in (2.5) and plotted for the particular 
mouse in Figure 2.3 has shown to improve upon the issues found with the rational 
model. As the absolute value model is capable of a much faster rise in the dependant 
variable, the skew of the time of maximum absorbance shown in Figure 2.1 was 
better accounted. This model also showed better overall predictions of the maximum 
absorbance. However, much like the algebraic model, this model was unable to 
account for the false ‘peak’ in nanoparticle uptake; this refers to the high maximum 
absorbance that quickly drops off, most likely due to  poor coating of some of the
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injected nanoparticles. As neither the algebraic nor the rational model were able to 
account for this perceived error, the exponential model was created.
Figure 2.2 plots (2.4) for the same particular mouse of the above two models. 
This exponential model not only accounts for the false ‘peak’ of nanoparticles, but 
also gives a more ‘close up’ view of the retention phase of the experiment; this is of 
particular interest for the control effort portion of this research. As the goal of the 
control effort for the current model is to maximize the retention of nanoparticles in 
the bloodstream, the control effort is focused on the exponential model only. Using 
this model and the injection profiles described in (2 .6 ), the piecewise model was found 
and further used for the control effort described in C hapter 4.
Upon running the statistical tests it was found th a t the d a ta  within the lx  
and 2 x models were statistically similar and, therefore, we were able to  create average 
models, or ‘Master Mice’, for the lx  and 2x best fits of each model presented in 
Chapter 2. Confidence and prediction intervals were then found for each ‘Master 
Mouse’ for each model. These plots are now theoretically able to be used in real time 
in order to see adverse reactions and other possible issues during the experiment.
Several different control strategies were analyzed in Chapters 4 and 5. Initially, 
in Chapter 4 a tracking LQR controller with a DDE is used assuming the same 
initial injection as is used experimentally. Then, in Chapter 5 this same controller 
is used with different initial injections for the purpose of limiting the overall amount 
of nanoparticles required for the entire experiment. Then, the use of Dirac delta 
functions as a control strategy was analyzed to observe if a discrete number of 
injections would be at least as effective as the continuous injection in the LQR
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controller. Finally, as it is a more commonly used controller in the engineering or 
industrial settings, a tracking PID controller was used on the DDE. Each strategy 
was found to be efficient and proficient a t tracking to a  desired target (in this case, 
tracking to a desired absorbtion). The to tal am ount of required nanoparticles (in /iL) 
was found along with the error for each model and these values are given in Tables 
5.1 and 5.4, respectively. Each strategy required a different amount of nanoparticles 
to reach the desired target. However, as the error and oscillation of the different 
solutions also varied, it is not entirely clear which strategy is the most efficient for 
experimental use.
While each method was shown to  be effective, the Dirac delta functions ap­
peared to be the most efficient as it yielded low error with minimal to tal injection 
and short run time. This control method was also able to  keep the absorbance value 
very close to  the target for the m ajority of the length of the experiment.
6.2 D iscussion  and Future W ork
Each control effort, with the possible exception of the PID control, applied to 
the exponential decay model shown runs within the tim e frame for which it could be 
used in an experimental setting. Currently, the confidence and prediction intervals 
described in Chapter 3 are in the beginning stage of being implemented for use in real 
time during the run of the experiments. W ith the models being created in real time 
it would be possible to see adverse reactions as they are happening and thus better 
treat the patient. Once this is accomplished, it is the goal to  implement a control 
strategy in an experimental setting as well. Each controller shows a different method
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with different results to  consider so the choice of control strategies to implement will 
most likely depend on the specific needs of the individual patient.
These models only show a single biological compartment (that is, they model 
the entire body at one time). Ideally, several different compartments will be added, 
such as the tumor, reticulo endothelial system, and bloodstream (similar to the 
models discussed in [IT]). Currently the experimental data does not provide the 
necessary information to show a multi-compartment model. The addition of these 
compartments will provide much better insight into where the nanoparticles are 
actually accumulating once they enter the body. The additional models will also 
provide more opportunities for control design strategies to  be applied. It would be of 
specific interest to minimize the nanoparticle elimination by the reticulo endothelial 
system and to maximize the nanoparticle uptake in the tumor. Ideally, these methods 
can also be used with other treatm ent strategies than  the nanoparticle dosages if 
enough data were provided for those methods.
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